YN001-004 in Patients With Coronary Atherosclerosis in Australia

StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: The study was terminated at the request of the Sponsor. Show 6 more changesShow less
    • Final enrollment: 3 participants (planned 24)
    • Study sites: 7 to 6
    • Primary and study completion dates changed from estimate of Jun 2026 to Jul 22, 2026
    • Start date changed from estimate of Feb 2026 to Feb 25, 2026
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: details revised at 1 of 7 entries
  2. Study sites: 6 to 7
    • Start date: Jan 2026 to Feb 2026
    v7
  3. Enrollment target: 12 to 24v6 Show 5 more changesShow less
    • Primary and study completion dates: Sep 2025 to Jun 2026
    • Start date: May 2025 to Jan 2026
    • Study sites: 5 to 6
    • Eligibility criteria expanded, about 97 words
    • Study description revised
  4. Start date: Apr 2025 to May 2025
    • Site details revised at 2 of 5 sites
    v5
  5. Start date: Feb 2025 to Apr 2025
    • Study sites: 2 to 5
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Site contacts updated at 2 of 2 sitesv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 16, 2024 to Feb 2025
    • Primary and study completion dates: Sep 11, 2025 to Sep 2025
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
Trial Details
NCT Number NCT06700720
Lead Sponsor Beijing Inno Medicine Co., Ltd.
Conditions
(from sponsor)		 Coronary Artery Disease, Coronary Atherosclerotic Disease
Related terms Coronary Artery Disease
Enrollment 3 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov